GMG

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Retrieved on: 
Martedì, Aprile 16, 2024
Autoantibody, FDA, American Academy, Immunoglobulin G, University, Clinical trial, Priority review, Risk, Safety, Food, ECI, Chronic inflammatory demyelinating polyneuropathy, Euronext, Research, Disease, PDUFA, Patient, Principal, AAN, CIDP, Biology, University of Minnesota, GMG, Autoimmunity, Pharmaceutical industry

“Our innovative approach to autoimmunity research is changing expectations for the global immunology community,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx.

Key Points: 
  • “Our innovative approach to autoimmunity research is changing expectations for the global immunology community,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx.
  • “The results of the ADHERE trial show that VYVGART Hytrulo reduces the risk of clinical deterioration in patients with CIDP while minimizing side effects and reducing the treatment burden.
  • VYVGART Hytrulo was well-tolerated, and the observed safety and tolerability profile was consistent with previous clinical trials.
  • Clinical trial data and real-world evidence presented during AAN continue to highlight the differentiated efficacy and safety profile of VYVGART and VYVGART Hytrulo, driving rapid, deep, and sustained improvement across disease scales and with different dosing schedules, including the ability for patients to achieve minimal symptom expression (MSE).

TeleRare Health™ Announces Launch of National Virtual Clinic for Rare Disease Patients

Retrieved on: 
Martedì, Aprile 30, 2024
Wilson's disease, Bangladesh Technical Education Board, Genomics, Kidney, SCID, Diagnosis, Safety, NIH, AI, Heart, Adrenoleukodystrophy, MD, Partnership, Children's National Hospital, DMD, FXS, Research, Human, Genetic testing, Disease, Patient, ALD, Pediatrics, Krabbe disease, Duchenne muscular dystrophy, PD, GMG, Fragile X syndrome, Pharmaceutical industry

MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- 8:00a (CET) April 30, 2024 - TeleRare Health™ launched today, a virtual clinic for Rare Disease patients and their families.

Key Points: 
  • MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- 8:00a (CET) April 30, 2024 - TeleRare Health™ launched today, a virtual clinic for Rare Disease patients and their families.
  • TeleRare Health aims to be the premier provider of virtual care for rare and genomic disease nationwide, envisioning a world where all patients have access to cutting edge diagnostics, treatments, and specialists.
  • "Significant breakthroughs have occurred in the management of rare disease," said Alex Katz, MD, medical geneticist and Chief Medical Officer of TeleRare Health.
  • We're overdue for a virtual clinic for the millions of Americans with rare disease conditions, and TeleRare Health's launch is cause for optimism.

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Giovedì, Aprile 11, 2024
American Academy, Myasthenia gravis, Risk, Safety, Infection, Dianthus, Neonatal Fc receptor, Therapy, Patient, AAN, Multifocal motor neuropathy, Caregiver, Complement component 1s, GMG, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.
  • DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy.
  • The oral presentation at AAN will highlight preclinical and in vitro data describing the differentiated safety profile and neurotransmission activity of DNTH103 and a review of previously released Phase 1 healthy volunteer data.
  • “We aim to demonstrate that DNTH103 may be a best-in-class treatment option with improved safety and infrequent self-administration that provides effective and consistent control of symptoms for people living with neuromuscular conditions.”
    Detailed presentation listings for the 2024 AAN Annual Meeting can be found on the meeting website: https://www.aan.com/events/annual-meeting .

Zero-Emission Truck Developer Windrose Technology Completes US$110 Million Series B Financing

Retrieved on: 
Giovedì, Aprile 11, 2024
TUV, Citylink, ASX, Goodman Group, Transport, Portfolio manager, BorgWarner, Shoulder, Stanford University, Kerry Logistics, Altitude, GMG, Greater China, HSBC, Goodman

HONG KONG, April 11, 2024 /PRNewswire/ -- Electric heavy-duty truck developer Windrose Technology has announced completion of the second phase of its Series B financing, raising the total funding for this round to US$110 million.

Key Points: 
  • HONG KONG, April 11, 2024 /PRNewswire/ -- Electric heavy-duty truck developer Windrose Technology has announced completion of the second phase of its Series B financing, raising the total funding for this round to US$110 million.
  • Windrose Technology is building the next generation of zero-emission and intelligent long-haul trucks that serve customers in moving consumer and industrial goods, offer cleaner and cheaper logistics around the world.
  • The Windrose EV truck has an 800V high-voltage fast-charging platform and can replenish 400km of range in under 36 minutes.
  • Leveraging our extensive global network and financing expertise, HSBC is uniquely positioned to provide unparalleled support for these pioneering tech companies."

Graphene Manufacturing Group Secures AU$2 Million Funding Grant from Queensland Government for Battery Pilot Plant

Retrieved on: 
Lunedì, Marzo 25, 2024
UQ, The Company, Partnership, GMG, Queensland Government, Lithium battery, State government, Pilot plant, State, Lithium

BRISBANE, AUS, Mar 25, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") announces that the Company has signed a Queensland Critical Minerals and Battery Technology Fund Agreement with the State Government of Queensland for a grant of AU$ 2 million towards the funding of GMG's proposed Automated Battery Pilot Plant for the manufacture of GMG's Graphene Aluminium Ion Battery.

Key Points: 
  • BRISBANE, AUS, Mar 25, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") announces that the Company has signed a Queensland Critical Minerals and Battery Technology Fund Agreement with the State Government of Queensland for a grant of AU$ 2 million towards the funding of GMG's proposed Automated Battery Pilot Plant for the manufacture of GMG's Graphene Aluminium Ion Battery.
  • The grant is for the payment of 50% of the capital cost of GMG's proposed Automated Battery Pilot Plant, up to a maximum of AU$ 2 million, for the manufacture of GMG's Graphene Aluminium Ion Battery.
  • The Pilot Plant would be constructed at GMG Richland's existing manufacturing facility, and the grant is conditional on various preconditions including GMG taking a final investment decision in the Battery Pilot Plant project.
  • GMG's CEO Craig Nicol stated, "We want to thank the Queensland Government and acknowledge its commitment to supporting the Critical Mineral and Battery Manufacturing Industry in the State.

Schneider Electric launches Materialize program for Scope 3 decarbonization of natural resources

Retrieved on: 
Mercoledì, Aprile 3, 2024
Carbon, Automation, Urban Saints, Schneider Electric, Electricity, Carbon accounting, GMG, Partnership, Catalysis, Metal, Software, Mineral, Digital technology, Glencore, Professional, Renewable energy

Materialize is a continuation of Schneider Electric’s suite of supply chain decarbonization programs from its Sustainability Business consulting division, which leverage the power of supply chain cohorts for renewable energy procurement at scale.

Key Points: 
  • Materialize is a continuation of Schneider Electric’s suite of supply chain decarbonization programs from its Sustainability Business consulting division, which leverage the power of supply chain cohorts for renewable energy procurement at scale.
  • “We are delighted to launch Materialize as our latest collaborative program to reduce Scope 3 emissions.
  • Both were created to engage thousands of suppliers simultaneously to drive swift and measurable action to reduce program sponsors’ Scope 3 emissions.
  • The portfolio builds on Schneider’s foundational initiative, The Zero Carbon Project , that provides resources and guidance to program participants, encouraging ambitious decarbonization goals with a deployment action plan to achieve it.

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US

Retrieved on: 
Venerdì, Marzo 22, 2024
MuSK protein, Science Translational Medicine, Charcot–Marie–Tooth disease, GMG, Patient, Myasthenia gravis, IND, Spinal muscular atrophy, Acetylcholine receptor, Safety, Muscle weakness, Fatigue, FDA, Food, Pharmaceutical industry

The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.

Key Points: 
  • The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.
  • The trial will take place in both US and European clinical sites.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: “This is an important milestone for NMD Pharma, enabling us to progress our lead development candidate NMD670 into a Phase 2b trial in the US in generalized myasthenia gravis patients with AChR and MuSK positive antibodies.
  • It follows positive Phase 1/2a data which provided proof-of-mechanism and where clinically and statistically significant effects were seen in patients.

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US

Retrieved on: 
Venerdì, Marzo 22, 2024
MuSK protein, Science Translational Medicine, Charcot–Marie–Tooth disease, GMG, Patient, Myasthenia gravis, IND, Spinal muscular atrophy, Acetylcholine receptor, Safety, Muscle weakness, Fatigue, FDA, Food, Pharmaceutical industry

The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.

Key Points: 
  • The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.
  • The trial will take place in both US and European clinical sites.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: “This is an important milestone for NMD Pharma, enabling us to progress our lead development candidate NMD670 into a Phase 2b trial in the US in generalized myasthenia gravis patients with AChR and MuSK positive antibodies.
  • It follows positive Phase 1/2a data which provided proof-of-mechanism and where clinically and statistically significant effects were seen in patients.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Retrieved on: 
Giovedì, Marzo 21, 2024
Janus, Research, MMN, Myasthenia gravis, Dianthus, GMG, CIDP, Half-life, Form, Patient, Complement component 1s, Magenta, Acetylcholine, American Academy, CMC, G&A, YTE, Drug, AAN, Investment, Therapy, PIPE, Magic, Multifocal motor neuropathy, Annual general meeting, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023, and provided an update on recent business achievements.

Key Points: 
  • DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the SEC.

The MeridianBet - Golden Matrix Transaction Secures Approval at GMGI Shareholder Assembly

Retrieved on: 
Mercoledì, Marzo 20, 2024
E-commerce, GMG, Proxy, Special, Acquisition

LAS VEGAS, NV, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Golden Matrix Group Inc. (NASDAQ:GMGI) (“GMGI”, “Golden Matrix” or the “Company”), a developer, licensor and global operator of online gaming and eCommerce platforms, systems and gaming content, today announced that its stockholders have voted to approve the terms of, and the issuance of shares of common stock in connection with, that certain previously announced Amended and Restated Sale and Purchase Agreement of Share Capital dated June 27, 2023 (as amended and restated from time to time, the “Purchase Agreement”) by and between the Company, as purchaser and Aleksandar Milovanović, Zoran Milošević and Snežana Božović, owners of MeridianBet Group, pursuant to which the Company seeks to acquire MeridianBet Group, at a special meeting.

Key Points: 
  • Commenting on the merger Zoran Milosevic, Chief Executive Officer of MeridianBet Group, said:
    "Today marks a major milestone for MeridianBet and I am thrilled that the shareholders of Golden Matrix have overwhelmingly voted in favor of the acquisition of MeridianBet.
  • By joining forces, we are not only expanding our reach but enhancing our ability to provide customers with a diverse and comprehensive offering whilst creating a leading global betting group.
  • The final voting results for each proposal voted on at the special meeting is set forth in a Current Report on Form 8-K filed by Golden Matrix with the U.S. Securities and Exchange Commission.
  • A full copy of the announcement can be viewed by visiting: https://www.nasdaq.com/articles/golden-matrix-stockholders-vote-to-acqui...